Bracco’s Commitment to Advancing the Future of Imaging Has No Boundaries
Bracco Diagnostics Inc. has had an exciting 2023 with the notable U.S. approval of their newest MR contrast agent VUEWAY® (gadopiclenol) solution for injection 485.1 mg/mL. Bracco’s newest agent is used to detect and visualize lesions with abnormal vascularity in the body and central nervous system at half the gadolinium dose compared to other macrocyclic GBCAs in approved indications in the U.S.
“Our newest MR agent offers a lot of differences versus other standard GBCA agents on the market, not only from a dosing regimen standpoint but also from a relaxivity perspective,” says Cosimo De Pinto, senior vice president of sales and marketing at Bracco Diagnostics. “Through close collaboration with our customers, we learned a lot about how VUEWAY® injection performed in routine clinical settings over the past 10 months. We’re looking forward to sharing those insights and experiences at RSNA in Chicago this year,” he says, adding “that this agent was also classified as a group II agent by the American College of Radiology (ACR), an important stamp of approval that reflects its complementary safety profile.”
Attendees can learn more about the uniqueness of VUEWAY® and how it supports patient care in a dedicated symposium, “The Future is Now, The New Novel GBCA Gadopiclenol,” on Monday, Nov. 27, from 9-10 am, S101AB, South Building, moderated by Max Wintermark, MD, MS, MBA, chair of the department of neuroradiology at The University of Texas M.D. Anderson Cancer Center.
In addition to VUEWAY®, at booth #3300 Bracco will showcase its full selection of products across all modalities, a comprehensive line of contrast agents, injectors, and informatics solutions for delivering the highest level of diagnostic care to patients amid some challenging conditions in healthcare. De Pinto says RSNA is truly ideal to meet with and listen to customers to ensure Bracco’s solutions are addressing their needs.
“We take nothing for granted and such interactions with our customers are fundamental in all we do.”
Customers are experiencing significant procedural growth at a time when they’re being asked to do more with less. This results in unprecedented downward pressure from a human resource standpoint and workflow considerations.
“At Bracco, our goal is to help customers navigate these challenges. We offer solutions in every modality including contrast imaging agents, contrast delivery systems, informatics solutions, and other service options. So we’re working together with our customers to ensure that we can help support them as they continue to work through this extraordinary growth in the industry,” De Pinto says.
The company is also partnering with Subtle Medical to collaborate on new AI algorithms to help better understand how AI can play a role in contrast-enhanced MR imaging.
“We’re excited about this new endeavor and look forward to sharing more at the RSNA,” De Pinto says.
Further, Bracco sees RSNA as an opportunity to give back, expanding its support of the Applied Radiology “Leaders on the Horizon” residency program through an unrestricted educational grant, which the publication has used to extend the program globally to include all diagnostic imaging modalities. Scholarships are given to six radiology resident applicants whose submitted research papers—three clinical research papers and three clinical review articles—are selected for publication by Applied Radiology.
“Our commitment to advancing the future of imaging has no boundaries. A great example of that is our support of the ‘Leaders on the Horizon’ where we look to identify the next leaders in imaging,” says De Pinto. “Residents from around the world are encouraged to submit original review papers for award considerations.”
Bracco is also happy to continue its work with the RSNA Research & Education (R&E) Foundation, entering the fourth year of its 10-year commitment to donate $450,000 to the program to support investigators in improving patient care through radiologic research and education.
“RSNA is always a great opportunity to connect with our customers and industry partners. It is the one meeting globally that helps our organization truly demonstrate its commitment to advancing the field of medical imaging and we do that in so many ways,” concludes De Pinto. “The goal for us is always a very simple one: we want to improve patients’ lives. So we come to the RSNA and share our comprehensive portfolio of products and solutions that help do that.”